Serina Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $130.0K | $0 | $-14.0K | $14.0K | $51.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $3.8M | $3.4M | $3.7M | $3.2M | $3.0M | $2.4M | $2.4M | $1.6M |
| SG&A Expense | $3.0M | $2.8M | $2.7M | $2.5M | $2.9M | $3.2M | $2.9M | $2.3M |
| Operating Income | $-6.8M | $-6.2M | $-6.4M | $-5.6M | $-5.9M | $-5.5M | $-5.3M | $-3.9M |
| Operating Margin | — | — | — | -4,280.8% | — | 39,635.7% | -37,942.9% | -7,580.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | $-4.8M | — | — | — |
| Income Tax Expense | — | — | — | — | $0 | — | — | — |
| Net Income | $-6.4M | $-3.3M | $-4.6M | $-6.4M | $-4.8M | $-2.7M | $1.4M | $5.2M |
| Net Margin | — | — | — | -4,960.0% | — | 19,571.4% | 10,071.4% | 10,203.9% |
| EPS (Basic) | $-0.55 | $-0.31 | $-0.45 | $-0.66 | $-0.49 | $3.10 | $0.16 | $0.61 |
| EPS (Diluted) | $-0.55 | $-0.31 | $-0.45 | $-0.66 | $-0.49 | $3.23 | $0.13 | $0.51 |
| Shares Outstanding (Basic) | 16.4M | 10.2M | 10.3M | 10.0M | 9.8M | 7.4M | 8.9M | 8.5M |
| Shares Outstanding (Diluted) | 16.4M | 10.2M | 10.3M | 10.0M | 9.8M | 7.4M | 10.8M | 10.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |